HBV News and Research

RSS

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Researchers document rare case of hepatitis B virus transmission

Researchers have documented a case of hepatitis B virus (HBV) transmission between two patients at a dentist's office in the United States.

4 Apr 2007

Hepatitis B found in sweat of Olympic athletes

A researcher in Turkey says hepatitis B may be contracted by means of sweat during contact sports.

1 Mar 2007

FDA approves Tyzeka for the treatment of adults with chronic hepatitis B

The Food and Drug Administration (FDA) has approved Tyzeka (telbivudine) for the treatment of adults with chronic hepatitis B (HBV), a serious viral infection that attacks the liver and can cause lifelong infection, scarring of the liver (cirrhosis), and eventually liver cancer, liver failure, and death.

26 Oct 2006

Fewer deaths from cancer in the U.S.

According to a new report fewer Americans are dying of cancer even though the rates of new cancers remains the same.

7 Sep 2006

Outcome of patients with hepatitis B and HIV infections referred for liver transplantation

A new study on HIV patients who also had Hepatitis B virus (HBV) found that better outcomes are possible if they are referred early for transplant and treated with a combination of drugs for HBV. It is essential to monitor the HBV status of these patients, however, in order to control the emergence of drug-resistant HBV infection.

3 May 2006

$1.5 billion needed to cover years supply of pediatric vaccines

A six-month stockpile of recommended pediatric vaccines would cost $1 billion and could cover more than 90 percent of U.S. children during a six-month interruption in production, say researchers at two Illinois universities.

19 Apr 2006

New hepatitis drug much more effective

Chronic infection with the hepatitis B virus (HBV) is responsible for an enormous burden of disease throughout the world, including up to half of all cases of cirrhosis, end-stage liver disease, and hepatocellular carcinoma, a cancer of the liver.

9 Mar 2006

Infants and adolescents vaccinated against hepatitis B are protected for over 10 years after immunisation

...concludes a study in this week’s issue of The Lancet. The authors state that booster doses of vaccine do not seem necessary to ensure long-term protection.

13 Oct 2005

Stressgen granted new U.S. patent for treatment of Hepatitis B

Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted Patent Number 6,921,534 covering fusion protein compositions comprised of a hepatitis B virus (HBV) antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins, and methods of treating an HBV infection using these fusion proteins.

7 Sep 2005

Molecular link between a viral infection and development of a common and fatal form of liver cancer

Researchers at The University of Texas M. D. Anderson Cancer Center have uncovered a crucial molecular link between a viral infection and development of a common and fatal form of liver cancer. In the process, they have identified a possible way to treat this disease as well as a number of other cancers.

26 Jul 2005

Crucial molecular link between a hepatitis B virus (HBV) and hepatocellular carcinoma (HCC)

21 Jul 2005

Sirna Therapeutics granted new UK patents

Sirna Therapeutics has announced that the United Kingdom (UK) Patent Office has granted the Company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with one or more chemical modifications targeting Vascular Endothelial Growth Factor (VEGF).

12 Jul 2005

Study shows using expanded critera donors is safe

Patients who had received livers from hepatitis B virus core antibody (HBcAb) positive (indicates prior exposure to hepatitis B) and/or hepatitis C virus (HCV) positive donors had similar graft and patient survival compared to patients who received HBcAb negative or HCV negative livers, according to a study by the University of Pittsburgh's Thomas E. Starzl Transplantation Institute.

25 May 2005

BMA calls for mass child vaccinations for hepatitis B virus (HBV)

The British Medical Association (BMA) has today called for all children in the UK to be immunised against a potentially fatal liver disease caused by the hepatitis B virus (HBV).

9 May 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B

Genetically engineered potatoes offer new hope in the fight against the Hepatitis B Virus (HBV), an acute sometimes fatal form of viral hepatitis caused by a DNA virus that persists in the blood serum and is transmitted by sexual contact or by transfusion or by ingestion of contaminated blood or other bodily fluids.

14 Feb 2005

Eleventh Edition of the Report on Carcinogens

The Department of Health and Human Services released its Eleventh Edition of the Report on Carcinogens today, adding seventeen substances to the growing list of cancer-causing agents, bringing the total to 246.

31 Jan 2005

Core promoter mutants of Hepatitis B Virus e Antigen associated with development of fulminant hepatitis and liver cancer

Scientists in Brown Medical School, Providence, USA, have found that core promoter mutants of Hepatitis B Virus e Antigen replicate at up to 10-fold higher levels in transfected human hepatoma cells than the wild-type virus.

9 Jan 2005

Peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B

Results from a large international clinical study reported in this week's issue of The Lancet showed that peginterferon alfa-2b produced sustained responses in patients with chronic hepatitis B. The investigator-initiated study is the largest clinical trial to date with peginterferon alfa-2b therapy for chronic hepatitis B.

7 Jan 2005